ClinicalTrials.gg
CompletedNCT04699032Updated Oct 26, 2024Results posted

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

A Phase 1 interventional study of Apraglutide in Chronic Kidney Disease, sponsored by VectivBio AG. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by VectivBio AG (part of Ironwood Pharmaceuticals, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 217 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
675th of 819
16 · median 72
Started
2020
with 34 others
Phase 1
93 of 988
15 open now
Registered
667th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 675th largest by enrollment of the 819 interventional ones that give a count, is one of 35 that started in 2020, is one of 93 in phase 1, and was the 667th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

Study of pharmacokinetics and safety of apraglutide in participants with normal and impaired kidney function.

Read the detailed description

A two stage design, open label, multi-center, non-randomized trial to evaluate the PK and safety of a single subcutaneous dose of 5 mg apraglutide in subjects with varying degrees of renal function. The renal function was calculated by the estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology (CKD-EPI) Creatinine Equation.

Part 1: 8 subjects with severe renal impairment (Cohort 1) and 8 subjects with normal renal function (Cohort 2).

Part 2: 8 subjects with moderate (Cohort 3) and 8 subjects with mild (Cohort 4). Enrollment into Part 2 was conditional on the results of Part 1.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Renal Function
  • Renal Impairment
  • Kidney Function
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants

  • Age between 18 and 75 years inclusive
  • Subjects who are willing and able to comply with the study procedures
  • Subjects able to understand and willing to sign the
  • (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight of >50 kg (110 lb).
  • Women of (WOCBP) on highly effective method of during the trial and for 1 month after the end of trial (EOT) visit. Sterilized or infertile or females.
  • Male subjects with a female partner of childbearing potential: highly effective methods of contraception and no sperm donation during the trial and for 1 month after (EOT) visit.

Healthy participants

  • No abnormalities (medical history, vital signs, , safety labs)
  • measured by CKD-EPI ≥90 mL/min/1.73 m2) at two screening visits
  • Demographically comparable to the group of subjects with impaired renal function:

Participants with impaired renal function

  • Severe renal impairment: eGFR \<30 mL/min/1.73 m2, but not requiring hemodialysis
  • Moderate renal impairment: eGFR ≥30 mL/min/1.73 m2 and \<60 mL/min/1.73 m2
  • Mild renal impairment: eGFR ≥60 and \<90 mL/min/1.73 m2

Exclusion criteria

Exclusion Criteria:

All Subjects

  • Renal transplant recipients
  • History of systemic infection
  • Any active or history of malignancies within the past 2 years
  • Acute or chronic medical or psychiatric condition
  • Treatment with an IMP within 30 days or 5 half-lives (whichever is longer) preceding the dose of IMP
  • Male subjects partners of who are unable to comply with the measures
  • History of intestinal adhesions and/or chronic abdominal pain
  • History of known colon polyps or family history of familial adenomatous polyposis
  • Positive blood screen for antibody, surface antigen or (HIV)-1 and -2 antibodies
  • Serum albumin concentration \<25 g/L (2.5 g/dL)
  • concentration \<90 g/L (9.0 g/dL)
  • (AST) or alanine amino transaminase (ALT) values >2 × (ULN)
  • Proteinuria of >3 g total >1.5 × ULN
  • Positive urine test for alcohol or illicit drugs at either Screening or admission.
  • Clinically significant abnormalities on 12-lead
  • Use of prescription or non-prescription drugs and dietary supplements within 7 days or five half-lives (whichever is longer) prior to Day 1. Stable concomitant medications may be given to subjects with renal impairment, if they are considered necessary for the welfare of the subjects.
  • History of regular alcohol consumption exceeding seven drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine, or 12 ounces [360 mL] of beer, or 1.5 ounces [45 mL] of hard liquor) within 3 months of Screening
  • Female subjects of childbearing potential who are unwilling or unable to use highly effective methods of contraception for the duration of the trial and for at least 1 month after the administration of the IMP; pregnant female subjects; female subjects planning to become pregnant during the duration of the trial and until 1 month after the administration of the IMP; breastfeeding female subjects
  • Blood donation of approximately 500 mL or more within 60 days prior to the dose of IMP. Plasma donations of approximately 500 mL or more within 28 days prior to the dose of IMP

Additional Exclusion Criteria for Healthy Subjects with Normal Renal Function

  • Evidence or history of clinically significant abnormalities
  • Evidence or history of clinically significant dermatological condition

Additional Exclusion Criteria for Subjects with Impaired Renal Function

  • Subjects requiring hemodialysis and/or peritoneal dialysis
  • Subjects with other clinically significant disease
  • Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease are not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the PK of apraglutide.
  • Screening BP ≥180 mmHg (systolic) or ≥110 mmHg (diastolic)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    eGFR (mL/min/1.73 m2): \<30 not on hemodialysis

    Drug: Apraglutide

  • Experimental
    Normal Healthy Match

    eGFR (mL/min/1.73 m2): ≥90

    Drug: Apraglutide

  • Experimental
    Moderate Renal Impairment

    eGFR (mL/min/1.73 m2): ≥30 to 60

    Drug: Apraglutide

  • Experimental
    Mild Renal Impairment

    eGFR (mL/min/1.73 m2): ≥60 to 90

    Drug: Apraglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Apraglutide

    Pharmacokinetic (PK) samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.

    Time frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1

  2. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide

    PK samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.

    Time frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events (AEs) that occurred after dosing the participant with the study drug. Participants with more than one TEAE were counted only once using the most severe event. Vital signs, triplicate 12-lead electrocardiograms, or clinical laboratory assessments considered clinically significant by the Investigator were reported as AEs.

    Time frame: Day 1 up to Day 14

  2. Number of TEAEs

    The Investigator used the adjectives mild, moderate, or severe to describe the maximum intensity of the AE. These were defined as follows: * Mild: did not interfere with participant's usual function * Moderate: interfered to some extent with participant's usual function * Severe: interfered significantly with participant's usual function. The Investigator systematically assessed the causal relationship of AEs to IMP/trial treatment using the definitions below: * Not related: Not reasonably related to the IMP. The AE could not medically (pharmacologically/clinically) be attributed to the IMP * Related: Reasonably related to the IMP. The AE could medically (pharmacologically/clinically) be attributed to the IMP. A serious AE (SAE) was classified as any AE that: * Resulted in death * Was life-threatening * Required or prolonged in-patient hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect in a neo

    Time frame: Day 1 up to Day 14

07

Results

Posted May 15, 2023

Participant flow

This study was performed in the United States of America between 08 December 2020 and 05 July 2021.

Participant flow — Overall Study
MilestoneSeverely Impaired Renal FunctionNormal Renal Function
Started88
Completed88
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Apraglutide

Pharmacokinetic (PK) samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.

Time frame:
5 minutes pre-dose up to 240 hours after dosing on Day 1
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Apraglutide
ng/mLSeverely Impaired Renal FunctionNormal Renal Function
Maximum Plasma Concentration (Cmax) of Apraglutide39.5 ± 13.765.8 ± 37.5
Statistical analysis
  • Severely Impaired Renal Function vs Normal Renal Function · Geometric least-square mean ratio: 0.620 · 90% CI 0.423 to 0.909
PrimaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide

PK samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.

Time frame:
5 minutes pre-dose up to 240 hours after dosing on Day 1
Reported as:
Mean · h*ng/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide
h*ng/mLSeverely Impaired Renal FunctionNormal Renal Function
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide3330 ± 11505050 ± 3170
Statistical analysis
  • Severely Impaired Renal Function vs Normal Renal Function · Geometric least-square mean ratio: 0.694 · 90% CI 0.458 to 1.050
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events (AEs) that occurred after dosing the participant with the study drug. Participants with more than one TEAE were counted only once using the most severe event. Vital signs, triplicate 12-lead electrocardiograms, or clinical laboratory assessments considered clinically significant by the Investigator were reported as AEs.

Time frame:
Day 1 up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSeverely Impaired Renal FunctionNormal Renal Function
Number of Participants With Treatment-emergent Adverse Events (TEAEs)32
SecondaryNumber of TEAEs

The Investigator used the adjectives mild, moderate, or severe to describe the maximum intensity of the AE. These were defined as follows: * Mild: did not interfere with participant's usual function * Moderate: interfered to some extent with participant's usual function * Severe: interfered significantly with participant's usual function. The Investigator systematically assessed the causal relationship of AEs to IMP/trial treatment using the definitions below: * Not related: Not reasonably related to the IMP. The AE could not medically (pharmacologically/clinically) be attributed to the IMP * Related: Reasonably related to the IMP. The AE could medically (pharmacologically/clinically) be attributed to the IMP. A serious AE (SAE) was classified as any AE that: * Resulted in death * Was life-threatening * Required or prolonged in-patient hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect in a neo

Time frame:
Day 1 up to Day 14
Reported as:
Number · events
Number of TEAEs
eventsSeverely Impaired Renal FunctionNormal Renal Function
Any TEAEs73
Any Mild TEAEs41
Any Moderate TEAEs32
Any Severe TEAEs00
Any Treatment-Related TEAEs50
Any Serious TEAEs00
Any TEAEs leading to study discontinuation00

Adverse events

Collected over Day 1 up to Day 14. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severely Impaired Renal Function0/8 (0%)0/8 (0%)3/8 (37.5%)
Normal Renal Function0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventSeverely Impaired Renal FunctionNormal Renal Function
Chest painGeneral disorders1/80/8
Injection site hemorrhageGeneral disorders1/80/8
Injection site papuleGeneral disorders1/80/8
NauseaGastrointestinal disorders1/80/8
VomitingGastrointestinal disorders1/80/8
Alanine aminotransferase increasedInvestigations1/80/8
Blood creatinine increasedInvestigations1/80/8
Neck painMusculoskeletal and connective tissue disorders0/81/8
HeadacheNervous system disorders0/81/8
Dermatitis contactSkin and subcutaneous tissue disorders0/81/8

Baseline characteristics

All participants.

Age, Continuous
Age, Continuous(years)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Mean66 (54 to 75)60 (56 to 70)63 (54 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Female000
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Hispanic or Latino112
Not Hispanic or Latino7714
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Severely Impaired Renal FunctionNormal Renal FunctionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White6511
More than one race000
Unknown or Not Reported000
Weight
Weight(kg)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Mean90.1 (77.7 to 98.2)86.7 (76.2 to 98.4)88.4 (76.2 to 98.4)
Height
Height(cm)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Mean171.9 (164.5 to 178.5)174.9 (168.5 to 181.0)173.4 (164.5 to 181.0)
Body mass index
Body mass index(kg/m^2)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Mean30.6 (24.4 to 33.7)28.3 (25.8 to 31.5)29.4 (24.4 to 33.7)
Estimated glomerular filtration rate
Estimated glomerular filtration rate(mL/min/1.73m^2)Severely Impaired Renal FunctionNormal Renal FunctionTotal
Mean21.3 (11.4 to 28.5)96.3 (91.4 to 108.0)58.8 (11.4 to 108.0)
08

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Prism Clinical Research, Inc.
    Saint Paul, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2021, 6 months.

Results were first posted in May 2023, 1 year 10 months after primary completion.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2020
First posted
Jan 7, 2021
StartActual
Dec 8, 2020
Primary completionActual
Jul 5, 2021
CompletionActual
Jul 5, 2021
Results first posted
May 15, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04699032
Lead sponsor
VectivBio AG
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Dec 8, 2020
Primary completion
Jul 5, 2021
Completion
Jul 5, 2021
Results posted
May 15, 2023
Last update
Oct 26, 2024

Study contacts

Tomasz Masior
study director · VectivBio AG

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apraglutide

Start the discussion